Skip to content

Study · Not a test of the peptide alone · 1995

7 results

In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging.

Reubi JC

Journal of nuclear medicine : official publication, Society of Nuclear Medicine1 Oct 1995Cited by 92 (Europe PMC)

PMID7562054 (opens in a new tab)PepBankPUB-07562054
Publisher pageAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement

    In human growth hormone-producing adenomas, only 5 of 19 had VIP receptors.

    In plain wordsIn lab tests on human pituitary tumor tissue, only 5 of 19 growth hormone-producing tumors had VIP receptors.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    MixedVIP receptors in growth hormone-producing adenomas
    Study

    humann = 19

    Human tumor tissue sections, receptor autoradiography with 125I-VIP
    Outcome group
    Receptor activity and mechanism · Cancer

    Measurements

    Tumors with VIP receptors
    5 of 19
    growth hormone-producing adenomas

    Source sentences

    Summary
    but only 5 of 19 growth hormone-producing adenomas and no medullary thyroid carcinomas or Ewing sarcomas had VIP-R.
    1 context sentence
    Summary · context
    Three hundred thirty-nine human tumors were investigated for their VIP-R content by in vitro receptor autoradiography on tissue sections with 125I-VIP.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement

    In human tumor sections, VIP receptors were localized in the neoplastic cells of most carcinomas, metastases, lymphomas, astrocytomas, glioblastomas and meningiomas tested.

    In plain wordsIn lab tests on human tumor tissue, most of the tumor types tested had receptors that bind VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVIP receptor expression in carcinomas and other tumors
    Study

    humann: not reported in source

    Human tumor tissue sections, receptor autoradiography with 125I-VIP
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    VIP-R were characterized and localized in the neoplastic cells of most breast carcinomas, breast cancer metastases, ovarian adenocarcinomas, endometrial carcinomas, prostate cancer metastases, bladder carcinomas, colonic adenocarcinomas, pancreatic adenocarcinomas, gastrointestinal squamous cell car…
    1 context sentence
    Summary · context
    Three hundred thirty-nine human tumors were investigated for their VIP-R content by in vitro receptor autoradiography on tissue sections with 125I-VIP.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement

    In human neuroendocrine tumors, all differentiated and one-half of undifferentiated gastroenteropancreatic tumors, pheochromocytomas, small-cell lung cancers, neuroblastomas and inactive pituitary adenomas expressed VIP receptors.

    In plain wordsIn lab tests on human neuroendocrine tumor tissue, many tumor types had receptors that bind VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVIP receptor expression in neuroendocrine tumors
    Study

    humann: not reported in source

    Human tumor tissue sections, receptor autoradiography with 125I-VIP
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    Among neuroendocrine tumors, all differentiated and one-half of undifferentiated gastroenteropancreatic tumors, pheochromocytomas, small-cell lung cancers, neuroblastomas and inactive pituitary adenomas were found to express VIP-R.
    1 context sentence
    Summary · context
    Three hundred thirty-nine human tumors were investigated for their VIP-R content by in vitro receptor autoradiography on tissue sections with 125I-VIP.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  4. 04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement

    In human tumors, VIP receptors were in general found much more frequently than somatostatin receptors.

    In plain wordsIn lab tests on human tumor tissue, VIP receptors were found much more often than somatostatin receptors.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVIP receptor frequency versus somatostatin receptors
    Study

    humann: not reported in source

    Human tumor tissue sections, receptor autoradiography with 125I-VIP
    Comparator
    Somatostatin receptors
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    In general, VIP-R were found much more frequently than SS-R
    1 context sentence
    Summary · context
    Three hundred thirty-nine human tumors were investigated for their VIP-R content by in vitro receptor autoradiography on tissue sections with 125I-VIP.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  5. 05LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement

    In human medullary thyroid carcinomas and Ewing sarcomas, no VIP receptors were found.

    In plain wordsIn lab tests on human tumor tissue, medullary thyroid cancers and Ewing sarcomas had no VIP receptors.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeVIP receptors in medullary thyroid carcinomas and Ewing sarcomas
    Study

    humann: not reported in source

    Human tumor tissue sections, receptor autoradiography with 125I-VIP
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    but only 5 of 19 growth hormone-producing adenomas and no medullary thyroid carcinomas or Ewing sarcomas had VIP-R.
    1 context sentence
    Summary · context
    Three hundred thirty-nine human tumors were investigated for their VIP-R content by in vitro receptor autoradiography on tissue sections with 125I-VIP.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  6. 06LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement

    In all human tumors tested, the VIP receptors were of high affinity and specific for VIP and pituitary adenylate cyclase-activating peptide.

    In plain wordsIn lab tests on human tumor tissue, the VIP receptors bound VIP strongly and were specific for VIP and PACAP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableAffinity and specificity of tumor VIP receptors
    Study

    humann: not reported in source

    Human tumor tissue sections, receptor autoradiography with 125I-VIP
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    In all tumors tested, the VIP-R were of high affinity and specific for VIP and pituitary adenylate cyclase-activating peptide.
    1 context sentence
    Summary · context
    Three hundred thirty-nine human tumors were investigated for their VIP-R content by in vitro receptor autoradiography on tissue sections with 125I-VIP.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  7. 07LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement

    In human tumor sections, no cross-competition between VIP and somatostatin was identified.

    In plain wordsIn lab tests on human tumor tissue, VIP and somatostatin did not compete for the same receptor sites.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeCross-competition between VIP and somatostatin
    Study

    humann: not reported in source

    Human tumor tissue sections, receptor autoradiography with 125I-VIP
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    No cross-competition between VIP and SS could be identified.
    1 context sentence
    Summary · context
    Three hundred thirty-nine human tumors were investigated for their VIP-R content by in vitro receptor autoradiography on tissue sections with 125I-VIP.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.